#Portugal #ENLIGHTEN #Proteotype #Alchemi #Torres Vedras

Introduction to Alchemi®

In a significant advancement for cancer diagnostics, Proteotype Diagnostics has revealed its innovative data and orchestration platform, Alchemi®. This cutting-edge tool is set to transform how clinical workflows connect laboratory measurements and multi-country clinical data. Alchemi® is integral to the future development of Enlighten®, Proteotype's investigational blood-based multi-cancer test, and it aims to create a seamless integration across distributed laboratories.

What is Alchemi®?

Alchemi® serves as a proprietary platform designed to standardize and streamline laboratory measurements and healthcare workflows related to cancer diagnostics. By doing so, it enables the secure interoperability of data across various laboratory and health-record systems while fully complying with relevant standards such as HL7 FHIR and SNOMED CT. The primary goal of Alchemi® is to reduce the reliance on central testing facilities, making it easier to integrate Enlighten® into local care pathways.

Enhancing Diagnostic Accuracy

The Enlighten® test operates by measuring the body's response to tumor development through a laboratory kit. Alchemi® supports this process by governing analytical and machine learning workflows, enabling the generation of traceable outputs that clinicians can trust. This newfound accuracy is pivotal in improving the diagnosis and treatment of multiple cancer types, potentially leading to earlier interventions and better patient outcomes.

The Role of Data Harmonization

One of the most remarkable features of Alchemi® is its capacity to harmonize pseudonymized data generated in different countries and laboratory environments efficiently. The platform facilitates controlled development and validation of explainable machine-learning models and ensures regulatory-compliant traceability. With this infrastructure, clinical evidence from Proteotype's MODERNISED and INNOVATOR studies will be analyzed and governed securely, translating insights into improved future workflows.

Creating a User-Friendly Interface

In developing Alchemi®, user experience has not been overlooked. The platform will feature a multilingual clinician portal that simplifies the order process for tests, viewing results, and managing workflows. This interface is designed to provide clarity regarding how each output is generated, ensuring that healthcare professionals can make informed decisions based on reliable science.

Timeline and Funding Support

The 15-month development program for Alchemi® is set to commence on September 1, 2026, with approximately €499,000 secured from the European Innovation Council's Pre-Accelerator program. This significant funding reflects confidence in Proteotype’s vision, as it aims to enhance machine-learning optimization, multi-country data harmonization, cloud security, and the overall integration of healthcare technologies.

Experts Weigh In

Wesley Sukdao, CEO and Co-Founder of Proteotype, emphasized that Alchemi® represents more than the underlying biology and clinical studies associated with Enlighten®. Instead, it embodies the secure data and software infrastructure needed to translate complex laboratory measurements into reliable results that clinicians can confidently utilize. He stated, “As our evidence base grows across cancers, countries, and care settings, Alchemi® will help us manage that complexity while keeping Enlighten® scalable and accessible.”

Dr. Emma Yates, Chief Scientific Officer and Co-Founder, highlighted that a diagnostic platform must maintain high-quality standards and traceability while being sensitive to differences between populations and laboratory environments. Alchemi® is built to ensure that every aspect of data handling is controlled, explainable, and reproducible.

Professor Gonçalo Bernardes, Co-Founder and Chair of Proteotype's Scientific Advisory Board, underlined Alchemi®'s role in synthesizing biological signals with laboratory technology and machine learning. By bringing these elements together, Alchemi® is creating a robust infrastructure necessary for translating scientific discovery into a clinically viable diagnostic platform.

Conclusion

In conclusion, Alchemi® serves as a pivotal advancement in the realm of cancer diagnostics, ensuring that as the landscape of cancer detection evolves, Proteotype Diagnostics is at the forefront, providing healthcare professionals with the tools and insights they need to enhance patient care effectively. As development progresses, Alchemi® promises to refine the path toward earlier detection and better clinical decision-making, marking a noteworthy milestone in the fight against cancer.